Advances in Primary Biliary Cholangitis and Primary Sclerosing Cholangitis.

Authors

Sunny Sandhu, Aparna Goel

Published in

Seminars in liver disease. Sep 15, 2026. Epub Sep 15, 2026.

Abstract

Primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) are chronic cholestatic liver diseases that have undergone notable therapeutic advances in recent years. Recent advances in PBC have expanded treatment options beyond ursodeoxycholic acid, enabling earlier risk stratification and use of second-line therapies, allowing practitioners to personalize treatment. Meanwhile, multiple investigational agents are under evaluation in clinical trials for PSC, yet there remain no approved treatments. This review summarizes advances in epidemiology, diagnosis, and treatment of the underlying disease along with the extrahepatic manifestations associated with PBC and PSC. PBC has entered a treat-to-target era, while PSC remains without approved disease-modifying therapy despite a rapidly expanding trial pipeline.

PMID:
42743991
Bibliographic data and abstract were imported from PubMed on 16 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.